Halaven (eribulin mesylate) / Eisai, Knight Therap, Shenzhen Kexing Pharma - LARVOL DELTA

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) (clinicaltrials.gov) - P3 | N=333 | Active, not recruiting | Sponsor: Intensity Therapeutics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

An open-label phase II study: The efficiency and safety of anlotinib + eribulin in patients with HER2-negative metastatic breast cancer. (PubMed, Int J Cancer) - P2 | "The most common treatment-related adverse events (TRAEs) were neutropenia (67.14%) and leukopenia (68.57%), with 41.43% and 27.14% of patients experiencing grade 3/4 hematologic toxicities, respectively. These findings suggest that the combination of eribulin and anlotinib demonstrated encouraging efficacy and a manageable safety profile, offering a potential therapeutic option for patients with HER2-negative mBC."

Journal • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor • CDK4 • HER-2

Analysis of efficacy and safety of eribulin in the treatment of advanced breast cancer in the real-world (ESMO 2025) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Breast Cancer • Oncology • Solid Tumor

KSHV and HPV modulate epithelial-to-mesenchymal transition in oral epithelial cells. (PubMed, mBio) - "For the first time, we show that knockdown of vimentin and eribulin treatment can restore E-cadherin and reverse epithelial-to-mesenchymal transition in KSHV- and HPV31-infected oral epithelial cells. These findings fill a gap in our understanding of oncogenesis and metastasis of oral cancers caused by KSHV and HPV31, revealing that vimentin may serve as a potential therapeutic molecular target for KSHV- and HPV-associated oral cancer."

Journal • Head and Neck Cancer • Human Papillomavirus Infection • Infectious Disease • Kaposi Sarcoma • Oncology • Oral Cancer • Sarcoma • Solid Tumor • CDH1 • VIM

Efficacy and safety of eribulin combined with anlotinib in patients with advanced liposarcoma and leiomyosarcoma (ESMO 2025) - No abstract available

Clinical • Metastases • Leiomyosarcoma • Liposarcoma • Oncology • Sarcoma • Solid Tumor

Phase I study data of a novel eribulin-based HER2 ADC: Safety and efficacy of SMP-656 in HER2-expressing solid tumor (ESMO 2025) - No abstract available

Clinical • P1 data • Oncology • Solid Tumor • HER-2

SYSKY-2023-1016-01: Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - P3 | N=200 | Recruiting | Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor • BRCA

Final survival outcomes of eribulin mesylate in combination with trastuzumab and pertuzumab as first-line chemotherapy for HER2-positive, locally advanced or metastatic breast cancer: results of the randomized, non-inferiority phase 3 JBCRG-M06/EMERALD study (ESMO 2025) - No abstract available

Clinical • Combination therapy • Head-to-Head • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Proliferation of tumor-related regulatory T cells in circulation dictates efficacy of chemoimmunotherapy in triple-negative breast cancer. (PubMed, Clin Cancer Res) - "Our results indicate that the proliferation and expansion of tumor-related clonotypes among circulating TREG cells are related to chemoimmunotherapy resistance particularly in TNBC."

IO biomarker • Journal • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2

Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer. (PubMed, J Natl Cancer Inst) - "Outcomes of post-T-DXd treatments differ significantly by MBC subtype and type of regimen administered. The use of SG immediately after T-DXd was associated with relatively short rwPFS across subtypes, highlighting some degree of cross-resistance with T-DXd."

Journal • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2

An exploratory study on the neoadjuvant treatment of early or locally advanced HER2-positive breast cancer patients with eribulin combined with trastuzumab and pertuzumab. (ChiCTR) - P4 | N=43 | Not yet recruiting | Sponsor: Zhejiang Cancer Hospital; Zhejiang Cancer Hospital

New P4 trial • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Inflammatory Breast Cancer • Oncology • Solid Tumor • HER-2

Aortitis after granulocyte-colony stimulating factor administration: A case report. (PubMed, Biomed Rep) - "In the present study, the case of a 59-year-old man is presented who received chemotherapy (eribulin) for liver metastases from sacral chordoma and subsequently developed acute aortitis after the administration of G-CSF...After discontinuing the antibiotics, the patient was monitored closely without further treatment. His condition improved within a few days; therefore, it was concluded that aortitis was induced by G-CSF."

Journal • Chordoma • Febrile Neutropenia • Hematological Disorders • Neutropenia • Oncology • Pain • CRP

A Phase Ib/II Clinical Trial of Toripalimab Plus Anlotinib in Taxane-Refractory HER2-Negative Recurrent or Metastatic Breast Cancer (ChiCTR) - P1/2 | N=99 | Not yet recruiting | Sponsor: Chongqing University Cancer Hospital; Chongqing University Cancer Hospital

IO biomarker • New P1/2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PD-L1

Eribulin in metastatic breast cancer in the real-world - the way forward in the Indian setting. (PubMed, J Chemother) - "Overall, the study shows low response rate with manageable toxicity. The findings highlight the need for further focused studies comparing eribulin with existing chemotherapies, especially in the Indian patients with disease heterogeneity and unique genetic makeup."

Journal • Real-world evidence • Breast Cancer • Hematological Disorders • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Neutropenia • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PGR

Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial. (PubMed, Breast Cancer Res) - P2 | "Ipatasertib combined with capecitabine or eribulin showed acceptable safety but was not tolerable with carboplatin plus gemcitabine. The addition of ipatasertib to capecitabine or eribulin shows a potential efficacy signal in this patient population, compared to historical monotherapy data of these treatments. Identifying biomarkers to predict response to AKT inhibitors in TNBC is crucial."

Journal • P2a data • Breast Cancer • Dental Disorders • Fatigue • Hematological Disorders • Neutropenia • Oncology • Solid Tumor • Stomatitis • Thrombocytopenia • Triple Negative Breast Cancer • PIK3CA

Spatial biomarkers of response to eribulin plus pembrolizumab in patients with metastatic triple negative breast cancer in the ENHANCE-1 trial. (PubMed, NPJ Breast Cancer) - "Responders exhibited higher stromal macrophage populations CD68 + , CD68+Vimentin + , CD68 + CD163+Vimentin+ as well as higher stromal HLA-DR + . Our results suggest that further studies on immune cell populations other than T-cells as predictive biomarkers for combination therapies in mTNBC are warranted."

Biomarker • Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD163 • CD20 • CD4 • CD68 • CD8 • FOXP3 • NCAM1 • VIM

Secondary Publication of Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Cutaneous Angiosarcoma 2025. (PubMed, J Dermatol) - "Five clinical questions were addressed, covering first-line chemoradiotherapy (CRT), management of residual lesions post-CRT, second-line treatment options, the role of pembrolizumab in tumor mutational burden-high cases, and treatment strategies for nonhead-and-neck angiosarcomas. Key recommendations include weakly recommending CRT for large (≥ 5 cm) nonmetastatic tumors, preferring drug modification over excision for residual lesions after CRT, and equally considering docetaxel, pazopanib, or eribulin for paclitaxel-resistant cases...Future directions emphasize the need for multicenter registry studies and prospective trials to refine treatment strategies. As advances in genomic medicine and immunotherapy evolve, guideline updates will be essential to ensure optimal patient care."

IO biomarker • Journal • Tumor mutational burden • Angiosarcoma • Non-melanoma Skin Cancer • Oncology • Sarcoma • Solid Tumor • TMB

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer (clinicaltrials.gov) - P3 | N=192 | Enrolling by invitation | Sponsor: Sun Yat-sen University

New P3 trial • Breast Cancer • Oncology • Solid Tumor

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) (clinicaltrials.gov) - P2 | N=13 | Active, not recruiting | Sponsor: Massachusetts General Hospital | Trial completion date: May 2025 ➔ Sep 2025

Trial completion date • Angiosarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Comprehensive assessments of pharmacokinetics and immunogenicity of farletuzumab ecteribulin, a novel antibody-drug conjugate against tumors expressing folate receptor α, in monkeys. (PubMed, J Pharm Biomed Anal) - "Following intravenous administration, the PK profiles of Tab and ADC were similar, while minimal levels of eribulin. No ADA against MORAb-202 was detected in postdose samples."

Journal • PK/PD data • Oncology • CTSB • FOLR1

TQB2930-III-01: TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer (clinicaltrials.gov) - P3 | N=416 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: University of Washington

New P2 trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ENG

A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=288 | Recruiting | Sponsor: Bliss Biopharmaceutical (Hangzhou) Co., Ltd | Trial primary completion date: Dec 2025 ➔ Jun 2025

Trial primary completion date • Oncology • Solid Tumor

SMU-pRMS: a novel cell line of pleomorphic rhabdomyosarcoma. (PubMed, Hum Cell) - "These cells exhibited high chemosensitivity to eribulin. In addition, mice inoculated with SMU-pRMS cells developed tumors after 4 weeks. Therefore, the SMU-pRMS cell line is a useful tool for investigating pRMS development and evaluating novel therapeutic agents."

Journal • Preclinical • Oncology • Rhabdomyosarcoma • Sarcoma • Solid Tumor

Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer (clinicaltrials.gov) - P2 | N=10 | Completed | Sponsor: Fudan University | Not yet recruiting ➔ Completed

Trial completion • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer